John Haeberle, MD
Family Medicine · Laramie, WYNPI 1619901907
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 75 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 10.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $377 and has fallen 94.3% since, to $22 in 2024.
Across 75 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$140
- GSK$113
- Amgen$106
- Abbott$102
- Vanda Pharmaceuticals Inc.$101
- Lilly USA, LLC$80
- plus $694 from 21 others
What the payments were for
- Food & beverage$1,335100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 8 | $140 |
| GSK | 7 | $113 |
| Amgen | 7 | $106 |
| Abbott | 5 | $102 |
| Vanda Pharmaceuticals Inc. | 3 | $101 |
| Lilly USA, LLC | 6 | $80 |
| AbbVie(2 entities) | 4 | $69 |
| Amarin Pharma, Inc. | 3 | $69 |
| Medtronic(2 entities) | 3 | $67 |
| Pfizer | 4 | $62 |
| Merck | 4 | $57 |
| Lundbeck LLC | 2 | $38 |
| Exact Sciences | 2 | $36 |
| Esperion Therapeutics, Inc. | 2 | $35 |
| AstraZeneca | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Sanofi-aventis U.S. LLC | 1 | $26 |
| Optinose US, Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Neotract Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Astellas Pharma US Inc | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $12 |
How this compares
$1,335 in reported general payments places this provider in the 85th percentile of 237 family medicine providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 30 | $29,915 |
| JardianceEmpagliflozin | 11 | $16,204 |
| MounjaroTirzepatide | 12 | $15,956 |
| Atorvastatin Calcium | 117 | $1,893 |
| Losartan Potassium | 73 | $1,151 |
| Levothyroxine Sodium | 90 | $1,027 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 40 | $949 |
| Pioglitazone Hcl | 35 | $854 |
| SynthroidLevothyroxine Sodium | 13 | $833 |
| Tamsulosin Hcl | 48 | $764 |
| Amlodipine Besylate | 60 | $679 |
| Pantoprazole Sodium | 51 | $655 |
| Metoprolol Succinate | 46 | $614 |
| Rosuvastatin Calcium | 37 | $540 |
| Pravastatin Sodium | 22 | $531 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $62 | $29,91530 claims |
| Boehringer IngelheimJardiance | $15 | $16,20411 claims |
| Lilly USA, LLCMounjaro | $80 | $15,95612 claims |
| AbbVieSynthroid | $69 | $83313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 237 family medicine providers in Wyoming.
Other family medicine in Laramie
- Darren MikesellLaramie$2K
- Andrea HabelLaramie$1K
- Joseph SchoeberCasper$176K
- James McLennanCasper$13K
- Karlynn SieversCasper$10K
- Eric LawrenceCasper$7K
- Jonathon MedinaCheyenne$6K
- Carol FischerCheyenne$6K
- Louis RoussalisCasper$5K
- Joseph MickelsonCasper$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.